What this means
This study looked at whether a single eye injection of UBX1325 is safe and how the body handles it. The study is finished, but no results have been posted, so we cannot say what it found.
Plain-English summary written by an AI model from the registry listing.
- Status
- Completed
- Who can join
- Ages 50 and over
- Where
- 8 sites, including California, Florida, Indiana
The science
- Registered title
- Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
- Trial ID
- NCT04537884 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
- What is tested
- UBX1325
- Sponsor
- Unity Biotechnology, Inc.
- Ages
- 50 Years to no maximum
- Dates
- First posted Sep 3, 2020 · updated Mar 10, 2022
Registry summary
A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
Sites (8)
- Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
- Salehi Retina Institute, Huntington Beach, California, United States
- MedEye Associates, Miami, Florida, United States
- Sarasota Retina Institute, Sarasota, Florida, United States
- Center for Retina and Macular Disease, Winter Haven, Florida, United States
- MidWest Eye Institute, Indianapolis, Indiana, United States
- Houston Eye Associates, Houston, Texas, United States
- Medical Center Ophthalmology Associates, San Antonio, Texas, United States
More aging trials in these states
California · Florida · Indiana · Texas